Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 2/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.38 |
| ▸ | GRM4 | Q14833 | 5/20 | 0.35 |
| ▸ | GRM8 | O00222 | 3/20 | 0.35 |
| ▸ | GRM6 | O15303 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2744927 | 1.00 | GRM2 (0.38) | GRM2GRM5GRM1GRM4GRM8 | |
| SCHEMBL3238992 | 1.00 | GRM2 (0.38) | GRM2GRM5GRM1GRM4GRM8 | |
| SCHEMBL14647478 | 1.00 | GRM2 (0.38) | GRM2GRM5GRM1GRM4GRM8 | |
| SCHEMBL13757663 | 1.00 | GRM2 (0.38) | GRM2GRM5GRM1GRM4GRM8 | |
| SCHEMBL2487735 | 1.00 | GRM2 (0.38) | GRM2GRM5GRM1GRM4GRM8 | |
| SCHEMBL16575073 | 1.00 | GRM2 (0.38) | GRM2GRM5GRM1GRM4GRM8 | |
| Hydrochloric Acid SCHEMBL3238987 | 0.98 | GRM2 (0.37) | GRM2GRM5GRM1GRM4GRM8 | |
| Hydrochloric Acid SCHEMBL32674363 | 0.98 | GRM2 (0.37) | GRM2GRM5GRM1GRM4GRM8 | |
| Hydrochloric Acid SCHEMBL2487732 | 0.98 | GRM2 (0.37) | GRM2GRM5GRM1GRM4GRM8 | |
| Hydrochloric Acid SCHEMBL2744924 | 0.98 | GRM2 (0.37) | GRM2GRM5GRM1GRM4GRM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2162431-B1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2017-06-07 | — | — | EP | disclosed |
| US-20150080569-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| US-8809266-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-20130274439-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2013-10-17 | — | — | US | disclosed |
| US-8420597-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2013-04-16 | — | — | US | disclosed |
| US-20130053577-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-02-28 | — | — | US | disclosed |
| US-20130053577-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-02-28 | — | — | US | disclosed |
| US-8178491-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20090257978-A1 | Antiviral coumpounds | GILEAD SCIENCES, INC. (US) | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274439-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | GRM2 4537/4885GRM5 3890/4885GRM1 4079/4885 |
| US-20090257978-A1 | Antiviral coumpounds | MAVS, ZC3HAV1, EIF2AK2 | GRM2 4834/4885GRM5 4823/4885GRM1 4841/4885 |
| US-20130053577-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | GRM2 4537/4885GRM5 3890/4885GRM1 4079/4885 |
| US-20150080569-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | GRM2 4537/4885GRM5 3890/4885GRM1 4079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.